Elevara Explores CDK4/6 Inhibition for Rheumatoid Arthritis Treatment
Elevara's lead candidate, ERV001, a CDK4/6 inhibitor, is set to enter Phase II testing as an add-on treatment for rheumatoid arthritis (RA).
Backed by $70m in Series A funding, Elevara Medicines aims to advance its CDK4/6 inhibitor, traditionally used in breast cancer, as an add-on RA therapy.
- The UK-based biotech plans to initiate Phase II testing of ELV001 by the end of 2025.
- The START-SYNERGY study will enroll 180 participants with inadequate response to methotrexate and TNF inhibitors.
According to CEO Emma Tinsley, the study will dose the first participant by the end of 2025.
Author's summary: Elevara explores CDK4/6 inhibition for RA treatment with ERV001.
More News
- PREDICTED TEAM: How Scorchers will line up for BBL opener
- Flight Booking, Cheap Flights, Air Tickets at Lowest Fare
- Hundreds stranded after IndiGo canceled 1,000 flights in India air travel chaos
- Gridlocked Halloween, 2025, @kaltgatzke flashbang film. I ...
- Cheap Domestic Flights in United States of America
- Sydney Sixers Vs Adelaide Strikers, WBBL 2025: SYS-W Beat AS-W By One Run Thanks To Ellyse Perry Century
- Congress gridlocked on key issues as year-end deadline looms
- Breaking: Loyalist troops foil coup attempt in Benin
- Delegates delayed at Brynglas Tunnels is Drakeford's fault
- Babar Azam, Mohammad Rizwan in focus: PCB clears Big Bash NOCs for Pakistan players, but with a catch